Dr Sinead Langan MB BCh BAO MRCP MSc PhD
About Sinead Langan
NIHR Clinician Scientist
- Sinead Langan's Contacts
- Keppel Street
- WC1E 7HT
- T: 0207 9272680
Sinead Langan's Background
I trained in Medicine at the Queen's University of Belfast and continue to work clinically at St John's Institute of Dermatology, Guy's and St Thomas' Hospital. I joined the School in 2011 having completed my PhD at the University of Nottingham and then gained post-doctoral experience as a visiting scholar at the University of Pennsylvania.
I am currently funded by a National Institute for Health Research Clinician Scientist award.
I am Chair of the European Dermatoepidemiology Network Steering committee (www.orgs.dermis.net/eden). I am also co-Chair and co-founder of the REporting of studies Conducted using Observational Routinely collected Data (RECORD) initiative (www.record-statement.org).
Sinead Langan's Affiliation
Sinead Langan's Teaching
I teach on a number of courses at the School, and I am currently the co-Course Organiser for the Certificate of Pharmacoepidemiology and Pharmacovigilance (PEPI)
Sinead Langan's Research
My research addresses three major areas:
- The epidemiology of skin diseases
- Reporting of observational research undertaken using routinely collected data
- Outcome measures research in eczema
1. The epidemiology of skin diseases
My research addresses an important research gap, the causes, consequences and treatment of skin disease. Little is known about the epidemiology of skin diseases. My work focuses in particular on using the power of routine data sources to provide answers for important research questions.
- In my recent research, I have established that the herpes zoster vaccine is very effective against herpes zoster and post-herpetic neuralgia in routine use in the general population in older individuals in the USA. This was the first study demonstarting effectiveness against post-herpetic neuralgia in routine use. These findings have great importance for countries currently considering introduction of the zoster vaccine into routine practice.
- Other zoster related work includes identfiying and highlighting to general practitioners the problem of under-prescription of antiviral therapy in the setting of acute herpes zoster, including amongst individuals at high risk of serious zoster-related complications, for example those with immunosuppression and complicated zoster.
- I am currently working on the epidemiology of herpes zoster in UK clinical practice and risk factors for zoster and adverse outcomes following herpes zoster
- I led the largest ever study of pyoderma gangrenosum and demonstrated increased mortality rates in these patients, even when compared to controls with inflammatory bowel disease and rheumatoid arthritis. Following this work, I am now working closely with gastroenterology colleagues in Nottingham to study skin diseases associated with inflammatory bowel diseases and coeliac disease
2.Reporting of observational research undertaken using routinely collected data
I co-founded the REporting of studies Conducted using Observational Routinely collected Data (RECORD) initiative (www.record-statement.org ) in 2012 in order to create reporting guidelines for studies undertaken using observational routinely-collected data.
3.Outcome measures research
I am also an active participant leading research as part of the Harmonising Outcome Measures in Eczema (HOME) initiative, which is an international initiative designed to devise a minimal set of core outcome domains to be used in all clinical trials and observational studies in eczema. This research will solve the problem of multiple inconsistent outcome measures which currently hamper evidence-based medicine by hindering comparison between different studies and the ability to combine the results of studies in systematic reviews and meta-analyses.
- Clinical databases
- Electronic health records
- Health outcomes
- Systematic reviews
Disease and Health Conditions
- Non-communicable diseases
- Skin disease
- European Union
- North America
- United Kingdom
- United States
Setting the RECORD straight: developing a guideline for the REporting of studies Conducted using Observational Routinely collected Data.
Langan, S.M. ; Benchimol, E.I. ; Guttmann, A. ; Moher, D. ; Petersen, I. ; Smeeth, L. ; Sørensen, H.T. ; Stanley, F. ; Von Elm, E. ;
Clin Epidemiol, 2013; 5:29-31
Herpes Zoster Vaccine Effectiveness against Incident Herpes Zoster and Post-herpetic Neuralgia in an Older US Population: A Cohort Study.
Langan, S.M. ; Smeeth, L. ; Margolis, D.J. ; Thomas, S.L. ;
PLoS Med, 2013; 10(4):e1001420
Assessment of clinical signs of atopic dermatitis: A systematic review and recommendation.
Schmitt, J. ; Langan, S. ; Deckert, S. ; Svensson, A. ; von Kobyletzki, L. ; Thomas, K. ; Spuls, P. ; Harmonising Outcome Measures for Atopic Dermatitis (HOME) Initiative, . ;
J Allergy Clin Immunol, 2013; 132(6):1337-47
Prevalence of Metabolic Syndrome in Patients with Psoriasis: A Population-Based Study in the United Kingdom.
Langan, S.M.; Seminara, N.M.; Shin, D.B.; Troxel, A.B.; Kimmel, S.E.; Mehta, N.N.; Margolis, D.J.; Gelfand, J.M.;
J Invest Dermatol, 2012; 132(3 Pt 1):556-62
The relationship between neurological disease and bullous pemphigoid: a population-based case-control study.
Langan, S.M. ; Groves, R.W. ; West, J. ;
J Invest Dermatol, 2011; 131(3):631-6
What causes flares of eczema in children?
Langan, S.M. ; Silcocks, P. ; Williams, H.C. ;
Br J Dermatol, 2009; 161(3):640-6
Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.
Langan, S.M.; Smeeth, L.; Hubbard, R.; Fleming, K.M.; Smith, C.J.; West, J.;
BMJ, 2008; 337:a180
What are the best outcome measurements for atopic eczema? A systematic review.
Schmitt, J. ; Langan, S. ; Williams, H.C. ; European Dermato-Epidemiology Network, . ;
J Allergy Clin Immunol, 2007; 120(6):1389-98
- → View all Dr Sinead Langan's publications